


**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

249-426

SERIAL NO.

10/575,261

APPLICANT

IIDA ET AL.

(Use several sheets if necessary)

FILING DATE

GROUP

April 10, 2006

4659 1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	TRANSLATION		
			CLASS	SUBCLASS	YES NO
WO 00/12113	03/2000	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

Majeau et al, "Mechanism of Lymphocyte Function-Associated Molecule 3-Ig Fusion Proteins Inhibition of T Cell Responses", Journal of Immunology, 1994, 152:2753-2767
da Silva et al, "Alefacet, an Immunomodulatory Recombinant LFA-3/IgG1 Fusion Protein, Induces CD16 Signaling and CD2/CD16-Dependent Apoptosis of CD2 ⁺ Cells ¹ ", The Journal of Immunology, 2002, 168:4462-4471
Cooper et al, "Alefacet selectively promotes NK cell-mediated deletion of CD45RO ⁺ human T cells", Eur. J. Immunol. 2003, 33:666-675
Sorbera et al, "Alefacet - Antipsoriatic", Drugs of the Future 2001, 26(6):527-532
EP 1 109 570 A0, June 27, 2001 (equivalent to above-listed WO 00/12113 (published on March 9, 2000))
Supplementary European Search Report dated November 19, 2007, issued in connection with EP 04 77 3776

*Examiner /Chun Dahl/ (08/07/2009) Date Considered _____

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)